公开(公告)号：US20250011727A1

公开(公告)日：2025-01-09

申请号：US18705735

申请日：2022-10-28

Applicant: GEORGIA TECH RESEARCH CORPORATION

Inventor： Andres J. GARCIA ,  Ankur SINGH ,  Adriana MULERO-RUSSE ,  Ana MORA BOZA ,  Maria M. CORONEL ,  Valeria M. JUAREZ

IPC: C12N5/071 ,  C12M1/00 ,  C12M1/12 ,  C12M3/00

Abstract: Disclosed herein are hydrogel structures and methods of making and use thereof. For example, disclosed herein are methods of making a device comprising a hydrogel matrix and a first chamber in the hydrogel matrix, the hydrogel matrix being derived from a prepolymer and the first chamber being perfusable. The methods can, for example, comprise blocking a first portion of a pre-polymerization solution with a first photomask, the pi-polymerization solution comprising the prepolymer, such that the pre-polymerization solution comprises an exposed portion and a first blocked portion. The methods can further comprise irradiating the exposed portion of the pi-polymerization solution and the first photomask with electromagnetic radiation, the first photomask being substantially opaque to the electromagnetic radiation. In some examples, the prepolymer within the exposed portion of pre-polymerization solution photopolymerizes to form the hydrogel matrix and the prepolymer within the first blocked portion does not photopolymerize and forms the first chamber.

公开(公告)号：US20240210384A1

公开(公告)日：2024-06-27

申请号：US18558026

申请日：2022-04-29

Applicant: GEORGIA TECH RESEARCH CORPORATION ,  EMORY UNIVERSITY

Inventor： Rebecca S. SCHNEIDER ,  Andres J. GARCIA ,  Wilbur A. LAM ,  Evelyn Kendall WILLIAMS ,  Karen E. MARTIN

IPC: G01N33/50

CPC classification number: G01N33/5091 ,  G01N2333/57 ,  G01N2333/96494

Abstract: A high-throughput, scalable, low-cost, on-chip microfluidic potency assay for nondifferentiated cells such as human mesenchymal stromal cells (hMSCs) with improved functional predictive power and recapitulation of in vivo secretory responses compared to traditional approaches. By comparison of hMSC secretory responses to functional hMSC-medicated immune cell suppression, on-chip microfluidic potency markers are identified with improved functional predictive power compared to traditional planar methods.

公开(公告)号：US20230256115A1

公开(公告)日：2023-08-17

申请号：US18015232

申请日：2021-07-08

Applicant: GEORGIA TECH RESEARCH CORPORATION ,  UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.

Inventor： Andres J. GARCIA ,  Maria M. CORONEL ,  Haval SHIRWAN ,  Esma S. YOLCU

IPC: A61K47/69 ,  A61K47/60 ,  A61K47/22

CPC classification number: A61K47/6903 ,  A61K47/60 ,  A61K47/22

Abstract: Disclosed are PD-L1 presenting compositions. The compositions may be used to effect immunomodulation in a variety of contexts. The compositions may be used to decrease rates of transplant rejection, including pancreatic islet cell transplantation. The compositions are useful for the treatment of type 1 diabetes.

公开(公告)号：US20200046780A1

公开(公告)日：2020-02-13

申请号：US16492441

申请日：2018-03-09

Applicant: University of Louisville Research Foundation, Inc. ,  Georgia Tech Research Corporation

Inventor： Haval SHIRWAN ,  Andres J. GARCIA ,  Esma S. YOLCU ,  Hong ZHAO ,  Devon HEADEN

IPC: A61K35/39 ,  A61K31/436 ,  A61K38/17 ,  A61K35/15 ,  A61K35/28 ,  A61K47/60 ,  A61K47/69 ,  C12N15/85 ,  A61P3/08

Abstract: Described herein are FasL-engineered biomaterials, as well as methods of making and using such FasL-engineered biomaterials, such as for immunomodulation, such as for inducing immunosuppression and specific immune tolerance, such as for preventing or reducing the risks of rejection of cellular or tissue grafts and/or the treatment of autoimmune disorders such as Type I diabetes. In specific embodiments, the FasL-engineered biomaterials are biotinylated microgels bound to SA-FasL.

公开(公告)号：US20240376438A1

公开(公告)日：2024-11-14

申请号：US18686552

申请日：2022-08-26

Applicant: GEORGIA TECH RESEARCH CORPORATION

Inventor： Susan Napier THOMAS ,  Edward BOTCHWEY ,  Andres J. GARCIA ,  Meghan O'MELIA

IPC: C12N5/09 ,  A61L27/18 ,  A61L27/38 ,  A61L27/52

Abstract: The present disclosure relates to a hydrogel biomaterial comprising cell adhesive peptides to generate in vivo tumor models.

公开(公告)号：US20240216271A1

公开(公告)日：2024-07-04

申请号：US18563543

申请日：2022-05-26

Applicant: GEORGIA TECH RESEARCH CORPORATION

Inventor： Andres J. GARCIA ,  Maria M. CORONEL

IPC: A61K9/06 ,  A61K47/34

CPC classification number: A61K9/06 ,  A61K47/34

Abstract: The present disclosure provides hydrogels, more particularly hydrolytically degradable hydrogels containing cleavable ester moieties and their use in such applications as tissue engineering and therapeutic delivery.

公开(公告)号：US20230310510A1

公开(公告)日：2023-10-05

申请号：US18157633

申请日：2023-01-20

Applicant: University of Louisville Research Foundation, Inc. ,  Georgia Tech Research Corporation

Inventor： Haval SHIRWAN ,  Andres J. GARCIA ,  Esma S. YOLCU ,  Hong ZHAO ,  Devon HEADEN

IPC: A61K35/39 ,  A61K47/69 ,  A61K47/60 ,  A61P3/08 ,  A61K31/436 ,  A61K35/15 ,  A61K35/28 ,  A61K38/17 ,  C12N15/85

CPC classification number: A61K35/39 ,  A61K47/6903 ,  A61K47/60 ,  A61P3/08 ,  A61K31/436 ,  A61K35/15 ,  A61K35/28 ,  A61K38/178 ,  C12N15/85

Abstract: Described herein are FasL-engineered biomaterials, as well as methods of making and using such FasL-engineered biomaterials, such as for immunomodulation, such as for inducing immunosuppression and specific immune tolerance, such as for preventing or reducing the risks of rejection of cellular or tissue grafts and/or the treatment of autoimmune disorders such as Type I diabetes. In specific embodiments, the FasL-engineered biomaterials are biotinylated microgels bound to SA-FasL.

公开(公告)号：US20210236686A1

公开(公告)日：2021-08-05

申请号：US17263021

申请日：2019-07-23

Applicant: Georgia Tech Research Corporation

Inventor： Woojin HAN ,  Andres J. GARCIA ,  Young C. JANG

IPC: A61L26/00 ,  A61M37/00 ,  A61J1/20

Abstract: Disclosed herein are hydrogels that can be loaded with myogenic agents, for instance muscle stem cells (MuSCs)/satellite cells, pro-myogenic factors, and combinations thereof. The hydrogels can be contacted with damaged muscle tissue, thereby facilitating muscle growth and repair. Further provided are methods of repairing muscle tissue in a patient in need thereof, said methods comprising contacting the muscle tissue with a composition comprising the hydrogel. Also provided herein are kits comprising the hydrogel composition and a substrate comprising at least one microneedle.

公开(公告)号：US20200078493A1

公开(公告)日：2020-03-12

申请号：US16492263

申请日：2018-03-09

Applicant: GEORGIA TECH RESEARCH CORPORATION ,  THE REGENTS OF THE UNIVERSITY OF MICHIGAN

Inventor： Ricardo CRUZ-ACUNA ,  Andres J. GARCIA ,  Asma NUSRAT ,  Jason R. SPENCE ,  Miguel QUIROS

IPC: A61L27/52 ,  A61K35/50 ,  A61K35/545 ,  A61K35/28 ,  A61K35/38 ,  A61L27/38

Abstract: Disclosed herein are synthetic hydrogel useful for the generation, storage and administration of cellular structures such as spheroids and organoids.

公开(公告)号：US20180133364A1

公开(公告)日：2018-05-17

申请号：US15576718

申请日：2016-05-26

Applicant: The University Court of the University of Glasgow ,  Georgia Tech Research Corporation

Inventor： Manuel SALMERON-SANCHEZ ,  Matthew J. DALBY ,  Andres J. GARCIA

IPC: A61L27/22 ,  A61L27/54 ,  A61L27/34 ,  A61K38/18

CPC classification number: A61L27/225 ,  A61K38/1825 ,  A61K38/1841 ,  A61K38/1866 ,  A61K38/1875 ,  A61L27/227 ,  A61L27/34 ,  A61L27/54 ,  A61L2300/414 ,  A61L2300/426 ,  A61L2400/18 ,  C08L89/00

Abstract: The invention provides materials presenting a biologically active matrix comprising a physiological fibrillar fibronectin network, such as implantable constructs, and their use for modulating cell behaviour and fate, including cell growth, proliferation and/or differentiation, such as for promoting tissue regeneration, for example, bone regeneration or vascularization. Also provided are constructs presenting a biologically active matrix comprising a physiological fibrillar fibronectin network for sustaining growth of stem cells or maintaining stem cells (maintaining stemness).